These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 29737107)
1. [Intravascular Large B-cell Lymphoma: a Clinical Analysis of 17 Cases]. Yang JJ; Chen XC; Tang Y; Shen K; Xie LP; Liu T Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):145-147. PubMed ID: 29737107 [TBL] [Abstract][Full Text] [Related]
2. Hemophagocytic syndrome and neurological involvement in a case of intravascular large B-cell lymphoma. Dou L; Wu C; Zeng Z; Zhu J; Su L; Wang T J Int Med Res; 2021 Sep; 49(9):3000605211006644. PubMed ID: 34590922 [TBL] [Abstract][Full Text] [Related]
3. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580 [TBL] [Abstract][Full Text] [Related]
4. [Intravascular large B-cell lymphoma: an important cause of fever of unknown origin]. Masaki Y; Miki M; Sakai T; Sawaki T; Fukushima T; Umehara H Brain Nerve; 2011 May; 63(5):435-41. PubMed ID: 21515922 [TBL] [Abstract][Full Text] [Related]
5. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases. Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188 [TBL] [Abstract][Full Text] [Related]
7. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261 [TBL] [Abstract][Full Text] [Related]
8. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. Yamamoto M; Watanabe K; Fukuda T; Miura O Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841 [TBL] [Abstract][Full Text] [Related]
9. Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review. Wen J; Xu J; Ji J; Zhang W; Zheng Q; Liu T; Zheng Y; Ma H Front Immunol; 2024; 15():1403376. PubMed ID: 39072323 [TBL] [Abstract][Full Text] [Related]
10. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
12. Successful treatment of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy and FDG-PET scan. Takahashi T; Minato M; Tsukuda H; Yoshimoto M; Tsujisaki M Intern Med; 2008; 47(10):975-9. PubMed ID: 18480585 [TBL] [Abstract][Full Text] [Related]
13. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729 [TBL] [Abstract][Full Text] [Related]
14. Primary bilateral adrenal lymphoma revealed by hemophagocytic syndrome. Alaoua A; Gilbert G; Ghannouchi N; Houchlef M; Letaief A; Bahri F Ann Endocrinol (Paris); 2011 Jun; 72(3):247-50. PubMed ID: 21640976 [TBL] [Abstract][Full Text] [Related]
15. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193 [TBL] [Abstract][Full Text] [Related]
16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
17. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989 [TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up]. Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712 [TBL] [Abstract][Full Text] [Related]
20. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]